Clinical Efficacy and Safety of CDK4/6 Inhibitors in Elderly Breast Cancer Patients

This study focuses on breast cancer, a disease with a high occurrence rate, especially in elderly patients aged 70 and above. The study aims to address the current gap in understanding the effects of a specific class of drugs, known as CDK 4/6 inhibitors (CDK 4/6i), in this age group. Current treatment guidelines for breast cancer are largely based on studies conducted on younger populations, which may not account for the unique health conditions, physical abilities, and aging factors of elderly patients. This research aims to provide a clearer picture of how CDK 4/6i can benefit and impact older women in real-world settings, potentially leading to improved care and treatment strategies tailored to their needs. During the study, participants will be monitored to evaluate the safety and effectiveness of CDK 4/6i. The primary goal is to assess the rate of side effects, both blood-related and non-blood-related, of any severity level in elderly patients while they are taking CDK 4/6i. The study will measure the incidence of these side effects over a 12-month period in elderly patients with both early and advanced breast cancer who are part of the patient cohort receiving CDK 4/6i treatment.